Supplementary Table 1 – Hematologic toxicity parameters

	LD	**SD**	**p value**
Minimal neutrophil count[1]	1056 ± 92.2	1050 ± 123.8	0.97[a]
Minimal Platelet count[1]	127 ± 8.6	122 ± 9.3	0.75[a]
Minimal hematocrit[1]	35.4 ± 0.61	34.4 ± 0.92	0.36[a]
Granulocyte colony stimulating factor use[2]	10%	7%	1.00[b]
Erythropoeitin use[2]	0%	11%	0.10[b]
Ribavirin dose reduction[2]	0%	7%	0.10[b]
Peginterferon dose reduction[2]	3%	4%	1.00[b]

---

[1] Mean ± standard deviation

[2] Percent of patients

[a] Student's t-test

[b] Fisher's exact test

Figure Legends

Figure 1. (a) The average level of HCV RNA (± standard error of the mean, SEM) during treatment. The solid line denotes SD, LD is marked by the dashed line. The dotted line marks the lower limit of detection. ** - $p<0.01$, * - $p<0.05$ (unpaired Student's t-test). (b) Kaplan-Meier analysis of time to negative serum HCV RNA on treatment (per protocol analysis). (c) First phase decline of HCV RNA levels. Patients who achieved SVR are marked with a circle, patients who did not achieve SVR by triangles (per-protocol analysis). (d) Second phase slope according to treatment group and result (per-protocol analysis).

Figure 2 – (a) Correlation of baseline serum IP-10 levels with liver IP-10 mRNA levels (normalized to GAPDH mRNA levels, arbitrary units). $r^2 = 0.489$, $p = 0.025$. (b) Serum IP-10 level fold induction relative to day 0 for LD (solid line, squares) and SD (dashed line, triangles). * $p<0.05$. (c) Day 2 IP-10 induction vs. baseline levels. LD marked with squares, SD with triangles. Open symbols mark treatment failure and filled symbols mark SVR.

Supplementary Figure 1 – Trial design. Patients were enrolled into the low dose (LD) or standard dose (SD) groups, for a planned duration of 24 weeks. At week 12 of treatment, patients who did not become HCV RNA negative were defined as non-responders and received extended therapy (ET) with full dose for another 36 weeks. Patients who relapsed after the end of treatment were given ET for 48 weeks.

Supplementary Figure 2 – Decay of IP-10 levels in stored serum samples. Pre-treatment IP-10 levels (all measured on December 2007) are displayed against the date the sample was drawn. Linear regression slope -0.24pg/(ml*day) (dashed line), r^2=0.13.

Supplementary Figure 3 - HCV RNA levels during initial therapy (solid line) and ET course (dashed line) for individual patients. ND - non-detectable. (a, b) Relapsers after initial LD treatment. (c) Non-responder to initial LD treatment. Switched to ET on week 16. (d) Relapser after initial SD treatment.